Nebula Research & Development LLC Takes Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Nebula Research & Development LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,814 shares of the company’s stock, valued at approximately $1,562,000. IDEXX Laboratories accounts for about 0.5% of Nebula Research & Development LLC’s investment portfolio, making the stock its 19th largest position.

Several other large investors have also added to or reduced their stakes in the business. Franklin Resources Inc. grew its stake in IDEXX Laboratories by 2.1% in the fourth quarter. Franklin Resources Inc. now owns 1,405,824 shares of the company’s stock valued at $780,303,000 after acquiring an additional 28,475 shares during the period. Morgan Stanley grew its stake in IDEXX Laboratories by 4.7% in the third quarter. Morgan Stanley now owns 1,064,514 shares of the company’s stock valued at $465,482,000 after acquiring an additional 48,095 shares during the period. Capital World Investors grew its stake in IDEXX Laboratories by 1.1% in the fourth quarter. Capital World Investors now owns 1,022,678 shares of the company’s stock valued at $567,648,000 after acquiring an additional 11,351 shares during the period. Norges Bank acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $512,190,000. Finally, Northern Trust Corp grew its stake in IDEXX Laboratories by 7.7% in the third quarter. Northern Trust Corp now owns 919,191 shares of the company’s stock valued at $401,935,000 after acquiring an additional 65,891 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX traded down $2.18 during midday trading on Tuesday, reaching $506.08. 112,347 shares of the company traded hands, compared to its average volume of 457,941. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The firm has a market capitalization of $41.80 billion, a price-to-earnings ratio of 49.20, a price-to-earnings-growth ratio of 4.06 and a beta of 1.33. The firm’s fifty day moving average price is $502.58 and its two-hundred day moving average price is $527.35.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Morgan Stanley reduced their price objective on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, June 6th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $580.38.

Insiders Place Their Bets

In other news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the transaction, the director now directly owns 161 shares in the company, valued at approximately $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.